NCT05753007View on ClinicalTrials.gov

A Clinical Trial of a Hemp-Derived, High Cannabidiol Product for Anxiety in Glioblastoma Patients

PHASE2TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

February 15, 2024

Primary Completion Date

February 11, 2025

Study Completion Date

February 11, 2025

Conditions
Glioblastoma
Interventions
DRUG

Cannabidiol (CBD)

Custom-formulated full-spectrum solution high in cannabidiol

DRUG

Placebo

Placebo solution

Trial Locations (1)

94143

University of California San Francisco Brain Tumor Center, San Francisco

Sponsors
All Listed Sponsors
collaborator

University of California, San Francisco

OTHER

collaborator

Center for Medicinal Cannabis Research

OTHER

lead

Mclean Hospital

OTHER